Article Text

COVID-19 related multisystem inflammatory syndrome in children (MIS-C): a hospital-based prospective cohort study from Kerala, India
  1. Arun Tiwari1,
  2. Suma Balan1,
  3. Abdul Rauf2,
  4. Mahesh Kappanayil3,
  5. Sajith Kesavan4,
  6. Manu Raj5,
  7. Suchitra Sivadas5,
  8. Anil Kumar Vasudevan6,
  9. Pranav Chickermane1,
  10. Ajay Vijayan2,
  11. Shaji Thomas John2,
  12. Sasidharan CK2,
  13. Raghuram A Krishnan7,
  14. Abish Sudhakar3
  1. 1Department of Rheumatology and Clinical Immunology, Amrita Institute of Medical Sciences, Cochin, Kerala, India
  2. 2Department of Pediatrics, Baby Memorial Hospital, Calicut, Kerala, India
  3. 3Department of Pediatric Cardiology, Amrita Institute of Medical Sciences, Cochin, Kerala, India
  4. 4Department of Pediatric Pulmonary and Critical Care, Amrita Institute of Medical Sciences, Cochin, Kerala, India
  5. 5Department of General Pediatrics, Amrita Institute of Medical Sciences, Cochin, Kerala, India
  6. 6Department of Microbiology, Amrita Institute of Medical Sciences, Cochin, Kerala, India
  7. 7Department of Cardiology, Baby Memorial Hospital, Calicut, Kerala, India
  1. Correspondence to Dr Suma Balan; sumabalan{at}gmail.com

Abstract

Objectives To study (1) epidemiological factors, clinical profile and outcomes of COVID-19 related multisystem inflammatory syndrome in children (MIS-C), (2) clinical profile across age groups, (3) medium-term outcomes and (4) parameters associated with disease severity.

Design Hospital-based prospective cohort study.

Setting Two tertiary care centres in Kerala, India.

Participants Diagnosed patients of MIS-C using the case definition of Centres for Disease Control and Prevention.

Statistical analysis Pearson χ2 test or Fisher’s exact test was used to compare the categorical variables and independent sample t-test or Mann-Whitney test was used to compare the continuous variables between the subgroups categorised by the requirement of mechanical ventilation. Bonferroni’s correction was used for multiple comparisons.

Results We report 41 patients with MIS-C, mean age was 6.2 (4.0) years, and 33 (80%) were previously healthy. Echocardiogram was abnormal in 23 (56%), and coronary abnormalities were noted in 15 (37%) patients. Immunomodulatory therapy was administered to 39 (95%), steroids and IVIg both were used in 35 (85%) and only steroids in 3 (7%) patients. Intensive care was required in 36 (88%), mechanical ventilation in 8 (20%), inotropic support in 21 (51%), and 2 (5%) patients died. Mechanical ventilation requirement in MIS-C was associated with hyperferritinaemia (p=0.001). Thirty-seven patients completed 3 months follow-up by April 2021, of whom 6 (16%) patients had some residual echocardiographic changes.

Conclusions Patients with MIS-C in our cohort had varied clinical manifestations ranging from fever with mild gastrointestinal and mucocutaneous involvement to fatal multiorgan dysfunction. Immediate and medium-term outcomes remain largely excellent except for the echocardiographic sequelae in a few patients which are also showing a resolving trend. Hyperferritinaemia was associated with the requirement of mechanical ventilation.

  • COVID-19

Data availability statement

Data are available upon reasonable request. Please contact sumabalan@gmail.com for any request related to data sharing.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request. Please contact sumabalan@gmail.com for any request related to data sharing.

View Full Text

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • Twitter @DrArunTiwari1, @doc_manu

  • Contributors AT took the lead in data curation, formal analysis, software and writing original draft. SB and AR took the lead in conceptualisation. SB took the lead in project administration, investigations, resources and supervision. MR, SB and MK took lead in writing review and editing the manuscript. AR, MK, MR, SK, SS, AKV, PC, AV, STJ, SCK, RAK, and AS provided critical feedback in conceptualisation, methodology, drafting and revisions which helped to shape the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.